Home » Stocks » Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. (DCPH)

Stock Price: $59.35 USD 0.49 (0.83%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 3.35B
Revenue (ttm) 7.15M
Net Income (ttm) -263.46M
Shares Out 56.38M
EPS (ttm) -5.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $59.35
Previous Close $58.86
Change ($) 0.49
Change (%) 0.83%
Day's Open 59.39
Day's Range 58.45 - 59.82
Day's Volume 284,966
52-Week Range 33.10 - 71.11

More Stats

Market Cap 3.35B
Enterprise Value 2.75B
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 56.38M
Float 37.72M
EPS (basic) -5.20
EPS (diluted) -5.15
FCF / Share -4.09
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.18M
Short Ratio 10.16
Short % of Float 11.09%
Beta 1.73
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 467.84
PB Ratio 5.10
Revenue 7.15M
Operating Income -272.92M
Net Income -263.46M
Free Cash Flow -228.58M
Net Cash 593.63M
Net Cash / Share 10.53
Gross Margin 349.55%
Operating Margin -3,816.00%
Profit Margin -3,683.70%
FCF Margin -3,196.06%
ROA -36.05%
ROE -62.54%
ROIC -56.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 9
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(23.00% upside)
Current: $59.35
Target: 73.00
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit25.00----
Operating Income-201-104-50.94-25.84-17.61
Net Income-192-99.85-50.28-25.94-19.82
Shares Outstanding42.8735.3916.7911.634.25
Earnings Per Share-4.48-2.82-2.99-2.23-4.67
Operating Cash Flow-149-86.78-36.70-23.09-13.27
Capital Expenditures-4.94-1.13-0.41-0.22-0.14
Free Cash Flow-154-87.91-37.11-23.31-13.41
Cash & Equivalents58029419757.4625.78
Total Debt17.6513.181.481.671.87
Net Cash / Debt56228119555.7923.91
Book Value546280184-140-115
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Deciphera Pharmaceuticals, Inc.
Country United States
Employees 255
CEO Steven L. Hoerter

Stock Information

Ticker Symbol DCPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DCPH
IPO Date September 28, 2017


Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.